Latest Conference Articles

Pharmacists can transform from only being prescription dispensers to health care hubs that offer comprehensive patient care and generate innovative revenue streams.

The key theme, regardless of strategy, is being an engaging member of the community and stepping outside of the counter.

This year’s conference is taking place from July 10 to 13 in Nashville, Tennessee.

Following his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter caught up with Drug Topics to discuss the pharmacists’ role in diabetes management.

Researchers explored patients with type 1 diabetes and overweight or obesity to understand the efficacy and safety of GLP-1s as adjunctive therapies.

In a recap of his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter, RPh, discussed the role of pharmacists in team-based diabetes care.

In an abstract presented at the American Diabetes Association 85th Scientific Sessions, researchers tested the effectiveness of an AI-driven program for improving glycemic control.

Jon Easter, RPh, discusses pharmacists’ ability to improve patient engagement in diabetes care following his presentation at the American Diabetes Association’s 85th Scientific Sessions.

Jon Easter, RPh, joined Drug Topics to discuss pharmacists’ roles within health care teams following his presentation at the American Diabetes Association’s 85th Scientific Sessions.

An ambulatory care pharmacist program in Washington State dramatically improved diabetes management by reducing A1c levels, increasing medication adherence, and providing comprehensive patient education.

Results from the CATALYST trial showed patients who received mifepristone had a mean HbA1c reduction of 1.47%,

Nathan Ramsbacher, PharmD, emphasizes that one of the most significant barriers to clinical quality is patients' inability to access crucial medications due to cost.

From 2019 to 2024, GLP-1 prescriptions among pediatric patients with type 2 diabetes increased from 12.3% to 60.9%.

The most frequent barriers to access to glucagon include cost, patient health literacy, and insurance coverage.

Researchers explored the prevalence of obesity-related complications and obesity medication use in US children and young adults with obesity.

The initiative focuses on managing medications for high-risk diabetes patients through a collaborative drug therapy agreement.

Researchers presented an abstract describing current racial disparities in CGM access and wear time to better inform quality improvement efforts.

Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.

In a retrospective study of obesity-related mortality, researchers explored US death trends before, during, and after the COVID-19 pandemic.

Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.

In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.

When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.

Data presented at ADA’s 85th Scientific Sessions showed patients who received physician education with clinical pharmacist outreach had significantly better A1c levels at 6 months compared to usual care.

Abstract researchers explored whether or not a pharmacist could serve as the lead of a diabetes coaching program, aiming to reduce medical expenditures and A1C levels for at-risk patients.

Check out our coverage from the American Pharmacists Association Annual Meeting and Exposition 2025!

In a session at PQA 2025, presenters discussed the impact of SDoH on health outcomes and how pharmacy teams can identify and address barriers.

Razanne Oueini, PharmD, MSc, CPHQ, discusses how rates of persistence to basal insulin were impacted after the IRA monthly cap.

Michael Hegener, PharmD, BCACP, discusses how workforce development can best address the evolving knowledge, skills, and abilities needed in community pharmacy practice.